CIDRAP newsletters options
The head of the WHO warns that ongoing surges in Europe and North America mark a critical moment for action.
The findings come as a report highlights rises in US nursing home cases, especially in the Midwest.
The 7-day average of new daily SARS-CoV-2 infections is higher than 81,000.
A hypothesis that says mask wearing could reduce the infectious dose is dangerous, some experts say.
Hospital room floors could be an underappreciated source of healthcare-associated pathogen spread, including those resistant to antibiotics, according to a study today in Infection Control and Hospital Epidemiology.
A PLOS Medicine study late last week found double the incidence of acute kidney injury (AKI) in hospitalized COVID-19 patients and a threefold higher mortality than in COVID-19–negative patients. Men, nonwhite patients, and those with comorbidities were at increased risk of developing AKI with COVID-19.
The drug reduced viral loads by a factor of 3.4 at one dosage tested.
Colorado, Illinois, and New Mexico report record daily cases, and illness levels are rising in 42 states.
Of HCWs with high-risk exposure, 7% tested positive, but 13% exposed outside the workplace tested positive.
Belgium becomes another European country to announce a national lockdown.
Telemedicine visits for urinary tract infections (UTIs) were associated with more appropriate antibiotic prescribing and decreased use of diagnostic and follow-up resources than virtual visits, according to the results of a primary care network study published yesterday in Infection Control and Hospital Epidemiology.
New data released today in Morbidity and Mortality Weekly Report (MMWR) show that household transmission of SARS-CoV-2, the virus that causes COVID-19, is common, occurs early after illness onset, and can originate from both children and adults.
Our weekly wrap-up of antimicrobial stewardship & antimicrobial resistance scans
A single student was the likely source of an outbreak that infected 76% of attendees.
In vaccine news, Moderna looks to having phase 3 trial results before December.
Yesterday the Centers for Disease Control and Prevention (CDC) reported two separate Escherichia coli O157:H7 outbreaks in the United States. Neither has an identified source, and one has already proved deadly.
A study yesterday in Science reports that the vast majority of patients with mild-to-moderate COVID-19 have stable levels of antibodies for at least 5 months.
Many facilities have less than 1 week's supply of at least one type of protective equipment.
"Cases are actually going up. And we know that, too, because hospitalizations are going up."
In recent weeks Europe has become one of the world's biggest pandemic hot spots.
